Results 41 to 50 of about 36,119 (263)

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

Health Technology Assessment, 2013
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt   +10 more
doaj   +1 more source

Recent Developments in Osteogenesis Imperfecta [PDF]

, 2015
Osteogenesis imperfecta (OI) is an uncommon genetic bone disease associated with brittle bones and fractures in children and adults. Although OI is most commonly associated with mutations of the genes for type I collagen, many other genes (some ...
Albert, Carolyne, Fritz, Jessica M., Harris, Gerald F., Shaker, Joseph L.   +3 more
core   +2 more sources

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health

Therapeutic Advances in Musculoskeletal Disease
Summary What is this summary about? This plain language summary describes the results of a clinical study, ROSALIA , which was published in the Journal of Bone and Mineral Research in 2024. The ROSALIA study looked at whether biosimilar denosumab has the
Richard Eastell, Sławomir Jeka, Maryam Lustberg, Colin Edgerton, Paweł Żuchowski, Barbara Vogg   +5 more
doaj   +1 more source

Activating the Osteoblastic USP26 Pathway Alleviates Multi‐Organ Fibrosis by Decreasing Insulin Resistance

Advanced Science, EarlyView.
The loss of Ubiquitin Specific Peptidase 26 (USP26) in osteoblasts results in decreased bone formation, as well as multi‐organ fibrosis associated with insulin resistance (IR). Mechanistically, the absence of USP26 reduces glycolysis and lactate accumulation, leading to decreased histone H3 lysine 18 lactylation (H3K18LA) in the promoter region of KH ...
Jiyuan Tang, Wenkai Ye, Liang He, Zhou Dan, Leilei Chang, Zijie You, Yuanyue Jiang, Guoqing Tang, Lianfu Deng, Changwei Li   +9 more
wiley   +1 more source

Rescuing Mitochondrial Dysfunction in Macrophages Prevents Osteonecrosis of the Jaw in Anti‐Resorptive Therapy

Advanced Science, EarlyView.
Schematic model showing the suggested mechanism that ZA induces classical activation of macrophages by impairing mitochondrial biofunction and inhibiting mitochondrial clearance to contribute to the pathological process of BRONJ. RAPA‐loaded nanoparticles ZDPR has shown potential in alleviating BRONJ lesions as well as treating osteoporosis or ...
Hang Zhang, Xin Shen, Haiyang Liu, Xinxi Yuan, Mumin Cao, Xuepeng Lv, Ziji Ling, Songsong Guo, Rongyao Xu, Xiang Li, Hongbing Jiang   +10 more
wiley   +1 more source

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [PDF]

, 2015
Purpose: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied.
A Lipton, Ada Braun, Alexander Paterson, Alison T. Stopeck, AM Brufsky, AO Hoff, AT Stopeck, CR Dunstan, D Amadori, Denise Yardley, F Saad, F Saad, Frank Kueppers, GA Block, Huei Wang, Ingo Diel, Janet E. Brown, Jean-Jacques Body, JJ Body, Jorge Arellano, K Fizazi, K Fizazi, Karim Fizazi, Katia Tonkin, L Gedmintas, Lawrence Karsh, LS Rosen, MG Kris, Michael Carducci, Miguel Martín, MR Smith, MR Smith, Neal Shore, NS Tchekmedyian, Paul Sieber, R Paparodis, RE Coleman, RG Russell, S Doshi, SL Ruggiero, ST Chang, Tapan Maniar, XGEVA® (denosumab) US Package Insert, Yasuhiro Fujiwara   +43 more
core   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Long-term care issues, specifically metabolic bone disorders, are a concern for people living with human immunodeficiency virus (PLWH) who undergo life-long antiretroviral therapy (ART).
Yusuke Kunimoto, Ryosuke Matamura, Hiroshi Ikeda, Hiroto Horiguchi, Satoshi Fujii, Masayoshi Kobune, Masahide Fukudo, Takaki Toda   +7 more
doaj   +1 more source

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain [PDF]

, 2015
The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in ...
Darbà, Josep, Kaskens, Lisette, Lothgren, Mickael, Sorio Vilela, Francesc   +3 more
core   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source